rare diseases

Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...

WALTHAM, Mass. — September 9, 2026 Revvity, Inc. announced that it has entered into a definitive agreement to acquire...

ASHBURN, Va. — September 8, 2026 Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) has...

Boston, Massachusetts, USA, September 1, 2026 Vertex Pharmaceuticals Incorporated has completed its acquisition of Crinetics Pharmaceuticals, Inc., strengthening its...

LAUSANNE, Switzerland, September 2, 2026 NewBiologix S.A. has entered into an agreement with Synastra Biotechnology Inc. to develop a...

PALO ALTO, Calif., August 31, 2026 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on medicines for...

PARAMUS, N.J. – August 25, 2026 Polaryx Therapeutics, Inc. announced continued operational progress toward initiating its SOTERIA Phase 2...

TOKYO, Japan — August 25, 2026 BioCryst Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has...

Philadelphia, Pennsylvania, August 19, 2026 Tolerance Bio, Inc., a biotechnology company focused on preserving, regenerating, and modulating thymic function,...

SAN RAFAEL, Calif., August 18, 2026 BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics,...